NASDAQ:CTIC
Delisted

Cti Biopharma Stock News

etoro logo Buy CTIC
*Your capital is at risk
$9.09
+0 (+0%)
At Close: Sep 22, 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTIO

Sobi to Acquire CTI BioPharma

01:06am, Wednesday, 10'th May 2023
Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI’s Closing Stock Price on May 9, 2023 SEATTLE, May 10, 2023 /PRNewswire/ — CTI BioPharma (Nasdaq: CTIC) (“CTI”), a
SEATTLE , May 4, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-
SEATTLE , May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-

VONJO Keeps CTI BioPharma A Buy

07:46am, Friday, 21'st Apr 2023
VONJO Keeps CTI BioPharma A Buy.
SEATTLE, Wash. , April 12, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies

These Are the Top 10 Holdings of David Kim

10:55pm, Monday, 06'th Mar 2023
David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 20
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -55.56% and 15.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
SEATTLE , March 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for bloo
SEATTLE , Feb. 23, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blo
CTI BioPharma has reported a better-than-expected Q3 print of 18.5M, which is a 40% growth QoQ, and we expect this growth to continue reaching close to USD60M in FY2022. CTIC's Vonjo (Pacritinib) is a
Here is how CTI BioPharma (CTIC) and Esperion Therapeutics (ESPR) have performed compared to their sector so far this year.
CTI BioPharma Corp. (NASDAQ:CTIC ) Q3 2022 Results Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Adam Craig - President, Chief Executive Officer and Interim Chief Medical O
CTI BioPharma (CTIC) delivered earnings and revenue surprises of 13.33% and 0.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Penny stocks to watch before November 2022 The post Best Penny Stocks To Buy? 4 To Watch Before November appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE